BIONATURIS (BIOORGANIC R.) D2015-JUNIO

Trading sesion


15/06/2015 Close

0.0100

Last price


0.05 mill. €

Capitalisation

0.00

Dif.(%)


0.00

% Year 2015

Excluded 16/06/2015

Last Trade

Last

0.0100

Ref.

0.0100

Dif.(%)

0.00

Volume (Shares)

66,987

Turnover (€x1000)

0.67

Security

Security name

BIONATURIS (BIOORGANIC R.) D2015-JUNIO

Ticker

86026

ISIN

ES0684980917

NIF

A-11811163

Capital Admitted

-

Shares Admitted

4.633.036

Nominal

-

Trading

Continuo

Liquidity Provider

GVC Gaesco Beka, S.V., S.A.

Registered Advisor

DCM ASESORES Dirección y Consultoría de Mercados, S.L.

Auditor

PAEZ & SERRANO AUDITORIES, S.L.U.

Address

AV DESARROLLO TECNOLOGICO 11, JEREZ DE LA FRONTERA

Contact

ir@bionaturis.com

Historical Summary

 2015 until 15/06

Capital Admitted (thousands of euros)

n/a

Shares (x 1,000)

4,633

Period Close Price (euros)

0.0100

Period Last Price (euros)

0.0100

Period High Price (euros)

0.0300

Period Low Price (euros)

0.0100

Capitalisation (thousands of euros)

46

Volume (thousands of shares)

366

Turnover (thousands of euros)

5

Company Profile

Bionaturis is a biotechnology-based group offering premium solutions for human and animal health applications. The Biotech Group comprises 4 companies (Bionaturis, Biobide, ZIP Solutions, and BNT Pacific LTD) and 2 subsidiaries (BNT China Biosciences and Biobide USA) located in three different continents, being worldwide references in their markets.

The matrix company of the Group, Bionaturis -Jerez de la Frontera, Cadiz-, is devoted to Animal Health, where is positioned as a partner of choice to bring high profitable products and services to the market place. By a B2B business model Bionaturis co-develops best-in-class prescription and non-prescription products for food production animals (FPAs) and pets. Cutting-edge antigens, probiotics and feed additives, among others, are part of the broad portfolio of products to meet the main needs of a steady growing sector.

Biobide -San Sebastian- is a preclinical CRO (Contract Research Organization) worldwide leader in the use of zebrafish as animal model for efficacy and toxicity assays for the Pharma, cosmetic, nutraceutical, agri-food, and environmental sectors.

ZIP Solutions –Barcelona- is a leading company in bioprocess having a relevant portfolio of international patents around its two main assets: Splittera and Zera Vaccines (subunit 2.0 and DNA vaccines). Its business model is based on the license of its proprietary systems to tier 1 companies in the sector.

Relevant Facts and Notices

Significant participations

Financial Reports

Photo Gallery

To obtain detailed information or information in other formats, please contact BME Market Data at marketdata@grupobme.es or visit the website www.bmemarketdata.es.

The information provided by the different websites of Grupo BME is for internal use only. For any commercial use and/or other usage that involves the redistribution of the information to third parties, it is required a prior and express permission from BME Market Data. Please contact us at marketdata@grupobme.es.

Copyright © Bolsas y Mercados Españoles 2017. All rights reserved. Disclaimer // Legal Disclaimer // Suppliers payment period